We report the case of a 32-year-old patient with ALL who developed autoimmune thrombocytopenia 2 months following allogeneic bone marrow transplantation. An IgM autoantibody against the platelet glycoprotein Ib/IX complex was observed. Treatment with high-dose steroids and intravenous immunoglobulin G failed to produce any benefit and the thrombocytopenia led to fatal gastrointestinal haemorrhage. The possible factors contributing to post-allograft thrombocytopenia and potential management strategies are discussed. Keywords: allogeneic bone marrow transplantation (BMT); autoimmune thrombocytopenia; platelet glycoprotein Ib/IX Autoimmune thrombocytopenia is a relatively common complication following allogeneic bone marrow transplantation and has been associated with poor survival.
gations revealed a diagnosis of common ALL with a (5;7) translocation.
After completing induction therapy he achieved morphological but not cytogenetic remission. He received a further course of idarubicin and cytarabine and three courses of FLAG (fludarabine, cytarabine, G-CSF), but despite being in consistent morphological remission following induction, cytogenetic remission was never attained. In November 1996, he underwent a T cell-depleted bone marrow transplant from a mismatched unrelated male donor (HLA-type of recipient: A1, A19(32), B5(52), B7, DRB1 0404, 0301; of donor: A1, A19(32), B5(51), B8, DRB1 0404, 0301). Conditioning consisted of CAMPATH-1G 20 mg/day for 5 days (days −9 to −5); thiotepa 5 mg/kg/day for 2 days (days −8 to −7); cyclophosphamide 60 mg/kg/day for 2 days (days −6 to −5); total body irradiation (1440 cGy) in eight fractions, and methylprednisolone 2 mg/kg/day for two days (days −2 and −1). Cyclosporin was given as prophylaxis against graft failure from day −1 until day +30. The patient was group O Rh negative and CMV seropositive and he received marrow from an A Rh negative, CMV seropositive donor. T cell depletion was performed ex vivo using Campath-1M. All blood products were irradiated. The patient had a fairly smooth initial post-transplant course. On day +10 he developed a maculopapular rash on his trunk, palms and soles which resolved with topical steroids. He engrafted on day +18 (neutrophils Ͼ0.5 × 10 9 /l) but did not become platelet independent until day +27. During weeks 3 and 4 post-transplant, the presence of CMV DNA in the blood was detected by PCR surveillance testing, although the patient was asymptomatic. He was therefore commenced on a 2 week course of foscarnet, rendering him CMV PCR negative. On day +32 he developed diarrhoea, vomiting and a widespread rash on his trunk, arms and legs. Although rectal biopsy failed to confirm graft-versus-host disease (GVHD) pathologically, he was treated empirically with intravenous steroids, and the rash resolved and the diarrhoea settled completely. He was discharged home on oral steroids on day +57 with a platelet count of 50 × 10 9 /l. On day +60 he was re-admitted with a generalised purpuric rash and mild epistaxis. His platelet count had fallen to 1 × 10 9 /l. Blood coagulation parameters were normal. A bone marrow aspirate revealed morphological and cytogenetic remission, with reduced but reasonable numbers of megakaryocytes. By this stage the CMV-PCR screening had again detected CMV DNA for 2 consecutive weeks and he was recommenced on foscarnet. His thrombocytopenia was treated with four adult doses of pooled leucocyte-depleted platelets; he was commenced on 1 g methylprednisolone intravenously for 3 days and a 3 day course of high-dose intravenous immunoglobulin G (0.4 g/kg/day) which was increased to 1 g/kg on the 4th day. Subsequently, HLA class I matched platelets were transfused and on day +65 he underwent a 4 liter plasma exchange. None of these measures produced any increment in his platelet count. Thirty-six hours later he developed a catastrophic gastrointestinal bleed and died as a result, on day +67. No post-mortem was performed.
Prior to the terminal event, samples were analysed for the presence of platelet-specific antibodies. Using the indirect platelet immunofluorescence test (PIFT) 3 a strong panreactive IgM antibody (average mean fluorescence intensity on 4 cells 557.0 vs 161.3 for negative control) was detected with no obvious reactivity in the IgG fraction. Specificity of the autoantibody was investigated by the monoclonal antibody-specific immobilization of platelet antigens (MAIPA) with an anti-IgM conjugate and murine monoclonal antibodies (mAbs) against GPIIb/IIIa (RFGP56, CD41), GPIb (CLB-MB45, CD42b), GPV (CLB-SW16, CD42d), GPIa/IIa (CLB-10G11, CD49b) and HLA class I (W6/32). Clear and exclusive reactivity of the IgM antibody with the GPIb/IX complex from four different donors irrespective of the threonine/methionine 145 mutation (HPA-2 system) in GPIb 4,5 was observed. The IgM antibody did not react with a recombinant baculovirus expressed 45 kDa amino terminal fragment of GPIb, indicating that it was either against GPIX or the stem structure of GPIb. 6 HPA genotypes of the recipient were determined by PCR-SSP 7 pre-and post-transplant and from the bone marrow donor using genomic DNA (see Table 1 ). The positive reaction with the HPA-3a primer with the post-transplant patient sample indicates the presence of leucocytes of donor origin.
Discussion
In the allogeneic bone marrow transplantation (BMT) setting, thrombocytopenia may be an isolated phenomenon or occur in association with multi-lineage cytopenia. Frequency of persistent thrombocytopenia post-BMT has been reported to be 5-37% 1,2 and may be due to non-immune or immune mechanisms. Non-immune causes include: failure of full megakaryopoietic reconstitution; relapse of the underlying malignancy; CMV infection (which may also cause an immune-related thrombocytopenia), or excessive Immune thrombocytopenia post-allograft may be alloimmune or autoimmune in aetiology. Alloimmune thrombocytopenia may be explained by donor-recipient antigenic discrepancy, with residual host B lymphocytes producing alloantibodies against platelets of donor origin. 8 Autoimmune thrombocytopenia applies to donor-versusdonor reactions and is probably attributable to immune dysfunction during post-transplant immunoreconstitution; indeed, loss of tolerance against other autoantigens with clinical overt autoimmune disease may occur at this time. ITP post-allograft has been associated with both CMV infection and GVHD 2, 9 and again, in these contexts, it may be isolated or part of a generalised immune-mediated pancytopenia. Notably, our patient had both evidence of CMV reactivation and clinical evidence of skin and gut GVHD, and loss of tolerance for platelet surface proteins was limited to a single glycoprotein complex which is generally the case in platelet autoimmunity.
The pre-and post-transplant HPA genotype of the patient in correlation with the donor's genotype showed that the patient had reconstituted donor leucocytes. Although the bi-allelic HPA-2 antigen system is localised on the amino terminal part of GPIb, both donor and recipient were HPA2a homozygous: indeed, the only discrepancy between donor and recipient HPA genotype was in the HPA-3 system. These antigens are, however, expressed on GPIIb␤, and the development of an anti-GPIb/IX antibody cannot be explained by the post-transplant allelic change of the HPA-3 system. This is the first time to our knowledge that an IgM antibody against GPIb/IX has been reported in a post-allograft patient. There are two obvious reasons why such antibodies might have remained undetected by others. First, many reference laboratories do not routinely use an anti-IgM conjugate in the indirect test. Secondly, GPIb is readily removed from the surface of donor panel platelets because of cleavage by calpain and such an antibody might remain undetected if stored platelets have been used for antibody detection. In ITP, autoantibodies directed against platelet surface antigens are detected in approximately 75-85% of patients when a direct test is applied. 3 Because of the extremely low platelet count in our patient a direct test could not be performed. The sensitivity of the serum test for detection of autoantibodies is significantly lower than that of the direct test, but the concentration of the IgM autoantibody must have been well above the detection threshold. Autoantibodies generally target epitopes on GPIIb/IIIa, GPIb/IX and GPV and other membrane glycoproteins including GPIa/IIa, GPIV and GPVI are less frequently involved. 3, 6 It is noteworthy that our patient had a profound thrombocytopenia in association with IgM antibodies. IgM-mediated destruction of platelets might be more severe when compared with IgG as complete activation of the complement cascade is more likely to occur with the former. IgM autoantibodies are usually observed in combination with IgG antibodies, and occurrence of IgM-only autoantibodies is rare. In cases of autoimmune haemolytic anaemia it is well documented that the treatment of IgM-mediated autoimmune hemolysis is more cumbersone than is that of an IgG-mediated haemolysis. This clear distinction in therapy sensitivity has not been documented for autoantibody-mediated thrombocytopenias but in this case there was obvious resistance to first-and second-line treatment.
There are sporadic reports on poor response to steroids in ITP patients with IgM autoantibodies, and certainly in this case the patient was steroid refractory. More aggressive and earlier institution of plasma exchange may, in retrospect, have been appropriate, given the information on the nature of the platelet autoantibody, and should perhaps be considered in a similar clinical setting in the future.
